Brief report · 29 Dec 2025
Conference abstractPublished 14 Nov 2016
Omics data strategy, precision medicine and modern biotechnology revolution
Nanjing BioSciKin Co. Ltd, China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The biopharmaceutical industry has quickly entered an era when fast evolving multidisciplinary omics technologies, historical precision medicine initiatives and disruptive bioinformatics techniques synergistically start to provide pivotal and strategic support for new drug development. Unprecedented amount of data is being generated to help discover and develop new generations of medications. Using examples, this talk covers several of the most important bioinformatic considerations in this strategy which includes: How do we efficiently manage the massive amount of data at different levels of precision to ensure a seamless data flow? How do we annotate and present these data to make it more comprehensible and deliverable? How do we design and execute the new clinical trials more efficiently and improve the success rate? Where are we and where are we going in this new precision medicine era?
Subjects
Biochemistry & BiotechnologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Metabolomics:Open Access.
Perspective · 29 Dec 2025
Metabolomics: Assessing Environmental Health and Risk
Brief report · 29 Dec 2025
Metabolite Quantification: Accuracy, Standards, Applications
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMetabolomics:Open Access
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Dongliang Ge”
